Core Insights - The Ministry of Industry and Information Technology and eight other departments have issued the "Implementation Plan for the High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)", aiming to establish a collaborative development system for the entire industry chain by 2030 [1] - The plan emphasizes enhancing the stable supply capacity of key traditional Chinese medicine raw materials, improving digital and green transformation levels, and achieving breakthroughs in key technologies [1] - The initiative aims to cultivate 60 high-standard traditional Chinese medicine raw material production bases and establish five innovation centers for the traditional Chinese medicine industry [1] Market-Related Areas - The policy encourages the use of modern scientific technology and traditional Chinese medicine research methods to study the efficacy and mechanisms of traditional Chinese medicine, which will lead to increased R&D investment and accelerated product iteration [1] - The continuous implementation of national and provincial standards for traditional Chinese medicine granules and slices will unify industry standards, posing short-term cost control challenges for some companies but ultimately benefiting larger enterprises with comprehensive industry chain advantages [2] - The current policy environment supports the inheritance and innovation of traditional Chinese medicine culture, providing a favorable market for the value return of branded traditional Chinese medicine [2]

Investment Rating - The industry investment rating is "Overweight" (maintained) [5] Core Insights - The report highlights the recent policy issued by the Ningxia Hui Autonomous Region government aimed at enhancing the regulatory framework for pharmaceuticals and medical devices, which is expected to promote high-quality development in the pharmaceutical industry [5] - The policy emphasizes support for the entire chain of traditional Chinese medicine (TCM) innovation, particularly focusing on the protection and development of local resources such as goji berries and licorice, which will benefit local TCM enterprises [6] - The report suggests that the policy will significantly improve the efficiency of product approvals for innovative drugs and medical devices, with specific measures to shorten approval timelines [6] - The report recommends focusing on companies with existing operations in Ningxia, especially those involved in the deep processing of local TCM resources, as well as innovative drug and medical device developers [6] Summary by Sections Recent Industry Performance - The industry has shown relative returns of -4.75% over the past month, -17.32% over the past three months, and -7.19% over the past year compared to the CSI 300 index [3] Policy Impact - The Ningxia policy includes measures to enhance the approval process for innovative drugs and medical devices, reducing the approval time for medical device production licenses from 30 to 20 working days and for second-class medical device renewals from 60 to 50 working days [6] - The policy encourages collaboration among local enterprises, universities, research institutions, and medical organizations to foster innovation in drug and medical device development [6] Investment Recommendations - The report advises investors to pay attention to companies that have a strong presence in Ningxia, particularly those involved in the development of local TCM resources, as well as those engaged in innovative drug and medical device research [6] - Specific companies mentioned for potential investment include Tongrentang, Dong'e Ejiao, Mindray Medical, Jiuzhoutong, and Tigermed [6]